Off-Target Uptake in Peptide-Conjugate Research

Off-target uptake refers to the association, internalization, accumulation, or processing of a peptide conjugate in cells or tissues outside the intended experimental target. It can arise through low-level target expression, interaction with related receptors, nonspecific membrane binding, endocytosis, serum-protein association, clearance pathways, linker instability, or the independent distribution of released payload.

Off-target uptake is one of the major interpretation questions in the evaluation of peptide-drug conjugates. Target-associated accumulation and off-target exposure can occur within the same experimental system, so researchers generally examine both rather than treating them as mutually exclusive outcomes.

This article discusses research methods and interpretation questions associated with off-target uptake in peptide-conjugate studies. It does not establish the safety, effectiveness, clinical suitability, or regulatory status of any peptide, payload, linker, conjugate, or finished product.

What Is Off-Target Uptake?

Off-target uptake is a broad research term. It may describe material detected in:

• cells lacking the proposed target
• cells with low target expression
• tissues outside the intended site
• clearance organs
• immune-cell populations
• extracellular compartments
• intracellular compartments not associated with the proposed pathway

The term does not identify one mechanism. Additional experiments are needed to determine why uptake occurred and what chemical species was detected.

Off-Target Uptake Is Not the Same as Off-Target Binding

Binding and uptake describe different stages.

Off-target binding may involve temporary association with:

• another receptor
• a related receptor subtype
• a membrane lipid
• a cell-surface protein
• an extracellular-matrix component

Off-target uptake occurs when material enters or accumulates within a cell or tissue. Binding can occur without internalization, while uptake may occur through pathways that do not require high-affinity binding to a defined receptor.

Low Target Expression Can Still Support Uptake

A tissue classified as target-negative may contain low but measurable quantities of the proposed receptor.

Low expression can be important when:

• the conjugate has high apparent affinity
• exposure is prolonged
• receptor internalization is rapid
• the target recycles to the cell surface
• the administered concentration is high relative to receptor abundance

Researchers should document how target-positive and target-negative classifications were established.

Related Receptors May Recognize the Peptide

A targeting peptide selected for one receptor may also interact with structurally related proteins.

Cross-reactivity may depend on:

• shared binding motifs
• receptor-family similarity
• peptide conformation
• conjugation position
• local concentration
• assay conditions

A receptor-binding result should therefore be supported by testing against relevant related receptors when those receptors are present in the biological system being studied.

Nonspecific Membrane Association

Peptides can interact with cell membranes through charge, hydrophobicity, amphipathic structure, or other physicochemical properties.

Membrane association may be influenced by:

• cationic amino-acid content
• hydrophobic residues
• peptide secondary structure
• lipid composition
• membrane potential
• extracellular pH

These interactions may occur in cells that do not express the intended target.

Cell-Penetrating Peptides and Broad Uptake

Cell-penetrating peptides are commonly investigated for their ability to cross or interact with cellular membranes.

When a targeting design includes a cell-penetrating sequence, researchers may need to separate:

• target-mediated binding
• target-mediated internalization
• general membrane association
• receptor-independent endocytosis
• direct membrane translocation

An increase in total uptake does not establish that the additional material entered through the intended targeting mechanism.

Endocytosis Can Occur Without the Proposed Target

Cells continuously sample extracellular material through multiple endocytic processes.

Peptide conjugates may enter through:

• macropinocytosis
• fluid-phase endocytosis
• adsorptive endocytosis
• clathrin-associated pathways
• caveolar pathways
• phagocytic processes in specialized cells

The relative contribution of each pathway may vary with cell type, concentration, incubation time, temperature, and conjugate structure.

Concentration Can Change the Apparent Mechanism

At lower concentrations, uptake may appear closely associated with a high-affinity target. At higher concentrations, receptor saturation or increased nonspecific interaction may change the observed pattern.

Concentration-dependent studies may help identify:

• saturable binding
• nonsaturable uptake
• changes in cellular localization
• membrane disruption
• aggregation-related uptake

A single concentration may not reveal whether uptake remains target dependent across the tested exposure range.

Exposure Time Matters

Short incubations may emphasize initial surface binding, while longer incubations may include internalization, recycling, degradation, and redistribution.

Time-course experiments can distinguish:

• rapid surface association
• gradual internalization
• intracellular accumulation
• signal loss
• export or recycling
• payload release

Comparing target-positive and target-negative systems at several time points can provide more information than an endpoint measurement alone.

Serum and Protein Binding

Peptide conjugates may bind to serum proteins, lipoproteins, enzymes, antibodies, or other biological components.

Protein association may alter:

• free conjugate concentration
• receptor accessibility
• apparent size
• circulation time
• cellular uptake
• distribution to clearance organs

Uptake observed in serum-free culture may not predict behavior under serum-containing or in vivo conditions.

Aggregation Can Increase Nonspecific Uptake

Hydrophobic payloads, multivalent structures, charge changes, or storage conditions may contribute to aggregation.

Aggregated material may interact differently with:

• cell membranes
• macrophages
• monocytes
• complement proteins
• filtration and clearance systems

Researchers may therefore examine particle size, soluble aggregate content, visible particles, and storage-dependent changes before interpreting cellular uptake data.

Immune-Cell Uptake

Phagocytic and antigen-processing cells may take up peptides, conjugates, particles, aggregates, or protein-associated material.

Cell populations that may be examined include:

• macrophages
• monocytes
• dendritic cells
• neutrophils
• specialized liver and spleen cells

Uptake by these cells may reflect clearance or immune processing rather than interaction with the intended targeting receptor.

Kidney Uptake and Renal Processing

Peptides and peptide-derived fragments may undergo glomerular filtration, tubular reabsorption, metabolism, or urinary elimination.

Renal signal can be influenced by:

• molecular size
• net charge
• plasma-protein binding
• peptide stability
• reabsorption mechanisms
• radiolabel or fluorescent-label retention

Detection in kidney tissue does not by itself establish expression of the intended target.

Liver and Reticuloendothelial Uptake

The liver and reticuloendothelial system participate in the processing of circulating molecules, protein complexes, particles, and metabolites.

Hepatic or splenic accumulation may reflect:

• metabolic processing
• protein association
• phagocytic uptake
• aggregation
• biliary elimination
• payload metabolism

These mechanisms should be considered separately from target-mediated tissue localization.

Linker Cleavage Can Separate Component Distribution

A peptide conjugate may generate several chemical species during circulation and tissue processing.

These may include:

• intact conjugate
• partially degraded conjugate
• peptide-linker fragments
• free or modified payload
• payload metabolites

Each species may show a different uptake and distribution pattern. Measuring total label alone may obscure these differences.

Released Payload May Enter Other Cells

Once released, a payload is no longer necessarily controlled by the targeting peptide.

Its subsequent behavior may depend on:

• membrane permeability
• ionization
• protein binding
• local concentration
• metabolic stability
• transporters
• efflux mechanisms

A payload detected in target-negative cells may have arrived as intact conjugate, as a released molecule, or as a metabolite. Those possibilities require different analytical tests.

Labels Can Produce Misleading Uptake Signals

Fluorescent and radioactive labels are valuable research tools, but the label may not remain attached to the intact conjugate throughout an experiment.

A signal may represent:

• intact labeled conjugate
• labeled peptide fragment
• labeled linker fragment
• labeled payload
• a trapped label-derived metabolite

Orthogonal chemical analysis can help determine which molecular species is responsible for the measured signal.

Surface Binding Can Be Mistaken for Internalization

A conjugate attached to the outer cell membrane may appear close to or within a cell when measured by some imaging methods.

Researchers may use:

• surface-stripping procedures
• acid washing
• membrane-impermeable quenchers
• confocal imaging
• subcellular fractionation
• flow-cytometry controls

No single method is universally sufficient. The method should be validated for the conjugate, label, and cell system being examined.

Controls Used in Off-Target Uptake Studies

Useful controls may include:

• target-negative cells
• receptor-knockout cells
• unconjugated targeting peptide
• scrambled peptide conjugates
• nontargeting peptide conjugates
• free payload
• linker-payload controls
• competition with excess ligand

Each control addresses a different question. A scrambled peptide, for example, may preserve approximate composition while changing sequence-dependent binding, but it may not reproduce the same conformation or physicochemical properties.

Blocking and Competition Studies

Receptor-blocking antibodies, excess ligand, or unconjugated peptide may be used to investigate target involvement.

A reduction in uptake after blocking may support a target-associated component. Residual uptake may reflect:

• incomplete blocking
• alternative receptors
• nonspecific membrane interaction
• fluid-phase uptake
• released payload

Blocking results should be interpreted with target-expression measurements and appropriate negative controls.

Quantifying Off-Target Uptake

Researchers may report:

• cell-associated concentration
• percentage of applied material
• fluorescence intensity
• radioactivity per mass of tissue
• target-to-nontarget ratios
• area under the tissue concentration-time curve
• intact conjugate and payload concentrations

The measurement unit and normalization method can substantially affect comparisons between experiments.

In Vitro Models

Cell-based studies can provide controlled comparisons of target expression and uptake pathways.

Limitations may include:

• simplified tissue architecture
• altered receptor expression
• absence of circulation
• limited extracellular matrix
• nonphysiological exposure conditions
• absence of metabolism and clearance

Results from one cell line should not automatically be generalized to all cells expressing the same target.

Three-Dimensional and Co-Culture Models

Spheroids, organoids, tissue slices, and co-culture systems may be used to study penetration and distribution across mixed cell populations.

These models can examine:

• surface-versus-core penetration
• target heterogeneity
• stromal interaction
• neighboring-cell uptake
• extracellular release

Model composition and target distribution should be characterized before uptake patterns are interpreted.

Animal Biodistribution Studies

Animal studies may examine blood, organs, tissues, urine, feces, and selected cell populations over time.

Interpretation may be limited by:

• species differences in the target
• different peptide-binding affinity
• different metabolic enzymes
• different clearance rates
• label instability
• sampling time

A suitable model should provide information about both the intended target and relevant off-target tissues.

Off-Target Uptake and Pharmacokinetics

Off-target uptake contributes to the measured disposition of a conjugate by removing material from circulation, creating tissue reservoirs, producing metabolites, or changing apparent clearance.

These relationships are examined more broadly in pharmacokinetics of peptide conjugates.

Questions for Evaluating an Uptake Study

Useful questions include:

• Was target expression measured in each cell or tissue?
• Was surface binding separated from internalization?
• Was the intact conjugate measured independently?
• Were peptide, payload, and metabolite signals distinguished?
• Were concentration and time dependence examined?
• Were serum proteins present?
• Was aggregation assessed?
• Were receptor-independent uptake pathways considered?
• Were clearance organs included?

Reading the Research Literature

The peer-reviewed review Peptide-Drug Conjugates: Design, Chemistry, and Applications, available through the National Library of Medicine, discusses targeting peptides, linker design, cellular delivery, conjugate stability, and other factors relevant to interpreting target-associated and off-target behavior.

Readers should distinguish design intent, qualitative imaging, quantitative uptake, tissue distribution, and chemical confirmation of the species being measured.

Final Perspective

Off-target uptake is not a single event and does not have a single experimental explanation. It may arise from low target expression, receptor cross-reactivity, membrane association, nonspecific endocytosis, serum binding, aggregation, clearance, linker cleavage, or payload redistribution.

Research programs should evaluate the intact conjugate, component fragments, released payload, relevant metabolites, target-positive systems, target-negative systems, and major clearance pathways.

Descriptions of preferential targeting should therefore be accompanied by evidence showing where else the conjugate and its components were detected and how those observations were measured.

InStrips products are offered for research and analytical use only. They are not intended to diagnose, treat, cure, or prevent any disease, injury, deficiency, absorption disorder, digestive condition, or medical condition.